Gilead Sciences makes fourth, and biggest, acquisition this year
US biotech major Gilead Sciences (Nasdaq: GILD) on Sunday announced that it has entered into a definitive agreement to acquire antibody-drug conjugate (ADC) specialist Immunomedics (Nasdaq: IMMU) for $88.00 per share in cash, more than double the $42.25 closing price on Friday, and with the news sending the latter’s shares of 107% to $87.49 in pre-market trading today.
The transaction, which values Immunomedics at around $21 billion, was unanimously approved by both the Gilead and Immunomedics boards of directors and is anticipated to close during the fourth quarter of 2020.
This is the fourth company acquisition this year for Gilead, which bought a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics in June for $275 million, paid $4.9 billion in April for Forty Seven, a maker of an experimental treatment that targets blood cancer, and in July bidding $300 million for a 49.9% stake in cancer immunotherapies developer Tizona Therapeutics, with an option to buy the remainder of the company for up to $1.25 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze